Rubedo Life Sciences develops novel small-molecule therapies engineered to selectively target various types of senescent cells using its ALEMBIC™ drug discovery platform. Its lead candidate, RLS-1496, is being advanced into Phase 1 studies for chronic atopic dermatitis and chronic psoriasis. The company is also developing programs targeting senescent cells in pulmonary diseases, including a program for idiopathic pulmonary fibrosis (IPF) that received a substantial CIRM grant last year. Rubedo’s pipeline targets multiple therapeutic areas tied to aging biology, such as pulmonary, dermatological, oncological, neurodegenerative and fibrotic disorders. The company is led by CEO & Co‑Founder Marco Quarta with Ali Siam as Chief Business Officer and is based in Sunnyvale, California. Financially, Rubedo recently closed a $40M Series A to fund its clinical and preclinical programs. Rubedo Life Sciences develops novel senolytic small‑molecule prodrugs via its proprietary ALEMBIC drug discovery platform to selectively target pathologic senescent cells that drive age‑related diseases. The company is advancing a pharmacological regenerative program for idiopathic pulmonary fibrosis (IPF), aiming to characterize senescent lung stem and progenitor cells and to screen a library of senolytic prodrugs on IPF primary cells. Rubedo plans to nominate a lead senolytic development candidate and to develop a clinical study using a humanized IPF model. The program is supported by a $1.45M award from the California Institute for Regenerative Medicine (CIRM). Rubedo has partnered with Cedars‑Sinai for the IPF research, with Cory Hogaboam, PhD, leading the Cedars‑Sinai effort. The company is based in Sunnyvale, CA, and is led by CEO and co‑founder Marco Quarta, PhD. Rubedo Life Sciences develops novel small-molecule therapies engineered to selectively target senescent, pro-inflammatory and pro-fibrotic cell populations using its proprietary ALEMBIC™ drug discovery platform. The company’s lead programs focus on respiratory diseases with high unmet need, including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Rubedo also has preclinical candidates in oncology and plans to pursue programs in neurodegenerative conditions, skeletal muscle disorders and other age-related diseases. The company plans to advance several compounds into IND-enabling studies in pulmonary diseases starting next year. Rubedo is based in Sunnyvale, California. It recently closed a seed financing to accelerate development of its clinical pipeline.

Total raised

$53M

Funding rounds

3

Latest round

Series A

Latest activity

Apr 2024